false
0001858685
0001858685
2023-11-09
2023-11-09
0001858685
BFRI:CommonStockParValue0.001PerShareMember
2023-11-09
2023-11-09
0001858685
BFRI:PreferredStockPurchaseRightsMember
2023-11-09
2023-11-09
0001858685
BFRI:WarrantsToPurchaseCommonStockMember
2023-11-09
2023-11-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 9, 2023
Biofrontera
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40943 |
|
47-3765675 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
120
Presidential Way, Suite 330
Woburn,
Massachusetts |
|
01801 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (781) 245-1325
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, par value $0.001 per share |
|
BFRI |
|
The
Nasdaq Stock Market LLC |
|
|
|
|
|
Preferred
Stock Purchase Rights |
|
|
|
The
Nasdaq Stock Market LLC |
|
|
|
|
|
Warrants
to purchase common stock |
|
BFRIW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
November 9, 2023, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results
for the three and nine months ended September 30, 2023. A copy of the press release is being furnished as Exhibit 99.1 attached hereto
to this Current Report on Form 8-K.
The
Company’s press release contains non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of
a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded
or included in the most directly comparable measure calculated and presented in accordance with United States generally accepted accounting
principles, or GAAP. Pursuant to the requirements of Regulation G, the Company has provided within the press release quantitative reconciliations
of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
The
information contained in this Item 2.02 in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference
in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
November
9, 2023 |
Biofrontera
Inc. |
(Date) |
(Registrant) |
|
|
|
/s/
E. Fred Leffler III |
|
E.
Fred Leffler, III |
|
Chief
Financial Officer |
Exhibit
99.1
Biofrontera
Inc. Reports Third Quarter 2023 Financial Results and Provides a Business Update
Conference
call begins at 10:00 a.m. Eastern time on Friday, November 10, 2023
WOBURN,
Mass. (November 9, 2023) – Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing
in the commercialization of dermatologic products, today reported financial results for the three and nine months ended September 30,
2023 and provided a business update.
Highlights
from the third quarter of 2023 and subsequent weeks included the following:
| ● | Total
revenues were $8.9 million, an increase of 106% from the comparable prior-year period |
| ● | Cash
and cash equivalents were $3.4 million and equity investment in shares of Biofrontera AG
was valued $3.3 million, both as of September 30, 2023 |
| ● | Subsequent
to the close of the quarter, raised $4.5 million in a registered direct offering priced at-the-market |
| ● | Appointed
life sciences industry veteran Heikki Lanckriet, Ph.D. to the Board of Directors |
| ● | Hired
Samantha Widdicombe as Senior Director to support and strengthen commercial relationships with key
strategic customer accounts |
| ● | Announced
positive results from a Phase 1 safety study evaluating photodynamic therapy (PDT) with three
tubes of Ameluz® |
| ● | Announced
last patient enrolled in a Phase 3 clinical study evaluating Ameluz®-PDT for
the treatment of superficial basal cell carcinoma |
| ● | Received
FDA approval for a new formulation of Ameluz |
Management
Commentary
“With
a strengthened commercial team and advancements in clinical trials intended to expand the Ameluz label, Biofrontera made
considerable progress during the third quarter, in line with our full-year expectations. Our commercial organization has succeeded
in the onboarding of significant, large new customers and increased the use of PDT as we enter the fourth quarter, historically
our seasonally strongest,” said Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera.
“In
the first nine months of 2023 we increased the number
of BF-RhodoLED® lamps in physician offices by 101, up sharply from 55 in the preceding quarter, enabling
increased adoption of Ameluz-PDT. We are proud of the resulting third quarter financial performance as product revenues more than doubled
compared with the prior year,” added Fred Leffler, Chief Financial Officer of Biofrontera Inc.
Third
Quarter Financial Results
Total
revenues for the third quarter of 2023 were $8.9 million, an increase of $4.6 million, or 106%, compared with $4.3 million for the third
quarter of 2022. This growth reflects higher sales of Ameluz due to increased adoption by dermatologists and
the buy-in impact due to a price increase.
Total
operating expenses were $13.5 million for the third quarter of 2023 compared with $8.0 million for the third quarter of 2022. Cost of
revenues was $4.6 million for the third quarter of 2023 compared with $2.2 million for the prior-year quarter, driven by higher Ameluz
product revenue. Selling, general and administrative expenses were $8.7 million for the third quarter of 2023 compared with $7.9 million
for the third quarter of 2022, with the increase primarily driven by higher personnel costs due to higher sales and medical headcount.
The
net loss for the third quarter of 2023 was $6.3 million, or $(4.64) per share, compared with a net loss of $2.6 million, or $(2.26) per
share, for the prior-year quarter, with all per-share figures on a split-adjusted basis.
Adjusted
EBITDA for the third quarter of 2023 was negative $3.9 million compared with negative $5.0 million for the third quarter of 2022, reflecting
higher revenues partially offset by increased SG&A costs. Adjusted EBITDA, a non-GAAP financial measure, is defined as net income
or loss excluding interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash
items.
Nine
Month Financial Results
Total
revenues were $23.5 million for the first nine months of 2023 compared with $18.5 million for the first nine months of 2022. The increase
was driven by higher adoption of Ameluz by dermatologists
and a higher average Ameluz selling price.
Total
operating expenses were $42.3 million for the first nine months of 2023 compared with $31.5 million for the first nine months of 2022.
Cost of revenues increased from the prior year to $12.1 million for the first nine months of 2023. Selling, general and administrative
expenses for the first nine months of 2023 were $30.1 million compared with $25.7 million for the first nine months of 2022, an increase
of 17.2% compared with the prior year, primarily driven by personnel-related expenses, sales-related travel, medical education
expenses and higher legal expenses.
The
net loss for the first nine months of 2023 was $23.7 million, or $(17.57) per share, compared with net income of $2.1 million, or $2.19
per diluted share, for the first nine months of 2022.
Adjusted
EBITDA was negative $15.8 million for the first nine months of 2023 compared with negative $14.1 million for the first nine months of
2022.
The
below table presents a reconciliation from net income (loss) to Adjusted EBITDA for the three and nine months ended September 30, 2023
and 2022:
| |
Three months ended
September 30, | | |
Nine months ended
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Net income (loss) | |
$ | (6,342 | ) | |
$ | (2,566 | ) | |
$ | (23,657 | ) | |
$ | 2,145 | |
Interest expense, net | |
| 142 | | |
| 89 | | |
| 256 | | |
| 160 | |
Income tax expense | |
| 1 | | |
| 1 | | |
| 20 | | |
| 31 | |
Depreciation and amortization | |
| 251 | | |
| 130 | | |
| 769 | | |
| 394 | |
EBITDA | |
| (5,948 | ) | |
| (2,346 | ) | |
| (22,612 | ) | |
| 2,730 | |
Change in fair value of contingent consideration | |
| 200 | | |
| (2,200 | ) | |
| 100 | | |
| (4,100 | ) |
Change in fair value of warrant liabilities | |
| (598 | ) | |
| (3,814 | ) | |
| (2,001 | ) | |
| (17,896 | ) |
Warrant inducement expense | |
| - | | |
| 2,629 | | |
| - | | |
| 2,629 | |
Change in fair value of investment, related party | |
| 2,212 | | |
| - | | |
| 6,635 | | |
| - | |
Legal settlement expenses | |
| - | | |
| - | | |
| 1,225 | | |
| - | |
Stock compensation expense | |
| 207 | | |
| 401 | | |
| 817 | | |
| 1,469 | |
Expensed issuance costs | |
| - | | |
| 320 | | |
| - | | |
| 1,045 | |
Adjusted EBITDA | |
$ | (3,927 | ) | |
$ | (5,010 | ) | |
$ | (15,836 | ) | |
$ | (14,123 | ) |
Adjusted EBITDA margin | |
| -44.1 | % | |
| -115.9 | % | |
| -67.5 | % | |
| -76.2 | % |
As
of September 30, 2023, Biofrontera had cash and cash equivalents of $3.4 million compared with $17.2 million as of December 31, 2022.
In addition, the Company had a $3.3 million investment in shares of Biofrontera AG as of September 30, 2023.
Financial
Expectations
Biofrontera
Inc. affirms expectations for full-year 2023 growth in revenue to be at least 25% compared with 2022, and expects to be cash flow positive
within approximately one and a half years. Subsequent to the close of the quarter, on November 2nd the company closed on a
$4.5 million registered direct offering priced at-the-market.
Conference
Call and Webcast
Biofrontera
Inc. will hold a conference call on Friday, November 10, 2023 at 10:00 a.m. Eastern time to discuss these results and answer questions.
| Date: | Friday,
November 10, 2023 |
| Time: | 10:00
a.m. Eastern time |
| Conference
Call: | 877-877-1275
(U.S. toll-free) |
| | 412-858-5202
(international) |
| Webcast: | Live
and 90-day replay webcast are available here and at investors.biofrontera-us.com. |
About
Biofrontera Inc.
Biofrontera
Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatologic
conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the
treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information,
visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter.
Forward-Looking
Statements
Certain
statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private
Securities Litigation Reform Act of 1995, as amended to date. We have based these forward-looking statements on our current expectations
and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations
disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control,
including, but not limited to, the impact of any extraordinary external events; any changes in the Company’s relationship with
its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s
ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s
ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the
coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation
and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials
of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will
be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications
for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is
consistent with the Company’s expectations; the Company’s ability to comply with public company requirements; the Company’s
ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that
may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers
are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and
reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking
statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Contact:
LHA
Investor Relations
Tirth
T. Patel
212-201-6614
tpatel@lhai.com
(Tables
follow)
CONDENSED
CONSOLIDATED BALANCE SHEETS
(In
thousands, except par value and share amounts)
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 3,422 | | |
$ | 17,208 | |
Investment, related party | |
| 3,341 | | |
| 10,548 | |
Accounts receivable, net | |
| 3,793 | | |
| 3,748 | |
Other receivables, related party | |
| 2,713 | | |
| 3,658 | |
Inventories, net | |
| 16,068 | | |
| 7,168 | |
Prepaid expenses and other current assets | |
| 274 | | |
| 810 | |
| |
| | | |
| | |
Total current assets | |
| 29,611 | | |
| 43,140 | |
| |
| | | |
| | |
Other receivables long term, related party | |
| - | | |
| 2,813 | |
Property and equipment, net | |
| 154 | | |
| 204 | |
Operating lease right-of-use assets | |
| 1,129 | | |
| 1,375 | |
Intangible asset, net | |
| 2,718 | | |
| 3,032 | |
Other assets | |
| 492 | | |
| 320 | |
| |
| | | |
| | |
Total assets | |
$ | 34,104 | | |
$ | 50,884 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
| 1,634 | | |
| 1,278 | |
Accounts payable, related parties | |
| 6,988 | | |
| 1,312 | |
| |
| | | |
| | |
Acquisition contract liabilities, net | |
| 7,211 | | |
| 6,942 | |
Operating lease liabilities | |
| 555 | | |
| 498 | |
Accrued expenses and other current liabilities | |
| 11,039 | | |
| 10,864 | |
Line of credit | |
| 1,697 | | |
| - | |
| |
| | | |
| | |
Total current liabilities | |
| 29,124 | | |
| 20,894 | |
| |
| | | |
| | |
Long-term liabilities: | |
| | | |
| | |
Acquisition contract liabilities, net | |
| 2,500 | | |
| 2,400 | |
Warrant liabilities | |
| 842 | | |
| 2,843 | |
Operating lease liabilities, non-current | |
| 562 | | |
| 848 | |
Other liabilities | |
| 38 | | |
| 21 | |
| |
| | | |
| | |
Total liabilities | |
| 33,066 | | |
| 27,006 | |
| |
| | | |
| | |
Commitments and contingencies (Note 18) | |
| | | |
| | |
| |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Preferred Stock, $0.001 par value, 20,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2023 and December 31, 2022 | |
| - | | |
| - | |
Common Stock, $0.001 par value, 15,000,000 shares authorized; 1,367,628 and 1,334,950 shares issued and outstanding as of September 30, 2023 and December 31, 2022 | |
| 1 | | |
| 1 | |
Additional paid-in capital | |
| 104,213 | | |
| 103,396 | |
Accumulated deficit | |
| (103,176 | ) | |
| (79,519 | ) |
| |
| | | |
| | |
Total stockholders’ equity | |
| 1,038 | | |
| 23,878 | |
| |
| | | |
| | |
Total liabilities and stockholders’ equity | |
$ | 34,104 | | |
$ | 50,884 | |
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(In
thousands, except per share amounts and number of shares)
(Unaudited)
| |
Three months ended September 30, | | |
Nine months ended September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| |
| | |
| | |
| | |
| |
Product revenues, net | |
$ | 8,879 | | |
$ | 4,290 | | |
$ | 23,423 | | |
$ | 18,467 | |
Revenues, related party | |
| 17 | | |
| 32 | | |
| 52 | | |
| 63 | |
| |
| | | |
| | | |
| | | |
| | |
Total revenues, net | |
| 8,896 | | |
| 4,322 | | |
| 23,475 | | |
| 18,530 | |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses | |
| | | |
| | | |
| | | |
| | |
Cost of revenues, related party | |
| 4,495 | | |
| 2,127 | | |
| 11,814 | | |
| 9,504 | |
Cost of revenues, other | |
| 95 | | |
| 98 | | |
| 262 | | |
| 425 | |
Selling, general and administrative | |
| 8,619 | | |
| 7,765 | | |
| 29,874 | | |
| 25,050 | |
Selling, general and administrative, related party | |
| 74 | | |
| 171 | | |
| 193 | | |
| 612 | |
Research and development | |
| 33 | | |
| - | | |
| 44 | | |
| - | |
Change in fair value of contingent consideration | |
| 200 | | |
| (2,200 | ) | |
| 100 | | |
| (4,100 | ) |
| |
| | | |
| | | |
| | | |
| | |
Total operating expenses | |
| 13,516 | | |
| 7,961 | | |
| 42,287 | | |
| 31,491 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (4,620 | ) | |
| (3,639 | ) | |
| (18,812 | ) | |
| (12,961 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | |
Change in fair value of warrant liabilities | |
| 598 | | |
| 3,814 | | |
| 2,001 | | |
| 17,896 | |
Warrant inducement expense | |
| - | | |
| (2,629 | ) | |
| - | | |
| (2,629 | ) |
Realized/Unrealized losses in investment, related party | |
| (2,212 | ) | |
| - | | |
| (6,635 | ) | |
| - | |
Interest expense, net | |
| (142 | ) | |
| (89 | ) | |
| (256 | ) | |
| (160 | ) |
Other income, net | |
| 35 | | |
| (22 | ) | |
| 65 | | |
| 30 | |
| |
| | | |
| | | |
| | | |
| | |
Total other income (expense) | |
| (1,721 | ) | |
| 1,074 | | |
| (4,825 | ) | |
| 15,137 | |
| |
| | | |
| | | |
| | | |
| | |
Income (loss) before income taxes | |
| (6,341 | ) | |
| (2,565 | ) | |
| (23,637 | ) | |
| 2,176 | |
Income tax expense | |
| 1 | | |
| 1 | | |
| 20 | | |
| 31 | |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) | |
$ | (6,342 | ) | |
$ | (2,566 | ) | |
$ | (23,657 | ) | |
$ | 2,145 | |
| |
| | | |
| | | |
| | | |
| | |
Income (loss) per common share: | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | (4.64 | ) | |
$ | (2.26 | ) | |
$ | (17.57 | ) | |
$ | 2.19 | |
Diluted | |
$ | (4.64 | ) | |
$ | (2.26 | ) | |
$ | (17.57 | ) | |
$ | 2.19 | |
| |
| | | |
| | | |
| | | |
| | |
Weighted-average common shares outstanding: | |
| | | |
| | | |
| | | |
| | |
Basic | |
| 1,366,842 | | |
| 1,136,291 | | |
| 1,346,264 | | |
| 978,018 | |
Diluted | |
| 1,366,842 | | |
| 1,136,291 | | |
| 1,346,264 | | |
| 980,251 | |
#
# #
v3.23.3
Cover
|
Nov. 09, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 09, 2023
|
Entity File Number |
001-40943
|
Entity Registrant Name |
Biofrontera
Inc.
|
Entity Central Index Key |
0001858685
|
Entity Tax Identification Number |
47-3765675
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
120
Presidential Way
|
Entity Address, Address Line Two |
Suite 330
|
Entity Address, City or Town |
Woburn
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
01801
|
City Area Code |
(781)
|
Local Phone Number |
245-1325
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common stock, par value $0.001 per share |
|
Title of 12(b) Security |
Common
stock, par value $0.001 per share
|
Trading Symbol |
BFRI
|
Security Exchange Name |
NASDAQ
|
Preferred Stock Purchase Rights |
|
Title of 12(b) Security |
Preferred
Stock Purchase Rights
|
Security Exchange Name |
NASDAQ
|
Warrants to purchase common stock |
|
Title of 12(b) Security |
Warrants
to purchase common stock
|
Trading Symbol |
BFRIW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_CommonStockParValue0.001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_PreferredStockPurchaseRightsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_WarrantsToPurchaseCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
From Oct 2023 to Oct 2024